Recent DTIL News
- Precision BioSciences Reports Fourth Quarter and Fiscal Year 2023 Financial Results and Provides Business Update • Business Wire • 03/27/2024 10:45:00 AM
- Precision BioSciences to Report Fourth Quarter and Fiscal Year 2023 Results on March 27, 2024 • Business Wire • 03/20/2024 08:30:00 PM
- Precision BioSciences Presents Preclinical Data Highlighting PBGENE-PMM as a Potential Therapy for Primary Mitochondrial Myopathy • Business Wire • 03/19/2024 11:00:00 AM
- Precision BioSciences Announces MHRA Approval for Partner iECURE to Expand Phase 1/2 Clinical Trial of ARCUS Gene Editing Program in OTC Deficiency • Business Wire • 03/06/2024 01:45:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/01/2024 01:00:25 PM
- Precision BioSciences Announces $40.0 Million Offering of Common Stock and Warrants • Business Wire • 03/01/2024 11:30:00 AM
- Form FWP - Filing under Securities Act Rules 163/433 of free writing prospectuses • Edgar (US Regulatory) • 03/01/2024 11:00:39 AM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 02/29/2024 10:19:00 PM
- Precision BioSciences Announces Proposed Public Offering of Common Stock and Warrants • Business Wire • 02/29/2024 09:01:00 PM
- Precision BioSciences Announces Non-Exclusive Patent License Agreement with Caribou Biosciences • Business Wire • 02/20/2024 12:00:00 PM
- Precision BioSciences Receives Pre-IND Feedback from US FDA for PBGENE-HBV as it Advances Towards Clinical Readiness • Business Wire • 02/14/2024 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/13/2024 01:29:39 PM
- Precision BioSciences Promotes Naresh Tanna to Vice President of Investor Relations • Business Wire • 02/13/2024 12:00:00 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/12/2024 04:00:46 PM
- Precision BioSciences Receives Initial $7.5 Million Cash Payment and Equity Investment from TG Therapeutics for Azel-Cel in Treatment of Autoimmune Diseases • Business Wire • 02/12/2024 12:00:00 PM
- Precision BioSciences to Effect a Reverse Stock Split • Business Wire • 02/09/2024 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/24/2024 12:19:20 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/24/2024 12:17:23 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/24/2024 12:15:20 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/24/2024 12:13:50 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/24/2024 12:11:11 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/23/2024 10:29:47 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 01/23/2024 09:27:56 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 01/22/2024 08:46:30 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 01/22/2024 08:42:29 PM
Endexx Corporation (EDXC) Leverages Global Market Trends and Legislative Reforms to Spearhead Growth in the Cannabis and Plant-Based Wellness Sectors • EDXC • Mar 27, 2024 3:01 PM
Applied UV, Inc. Announces Pricing of $2.76 Million Registered Direct and Private Placement Priced at the Market Under Nasdaq Rules • AUVI • Mar 27, 2024 2:51 PM
POET and MultiLane Collaborate to Develop High-Speed Pluggable Transceivers for AI Networks • POET • Mar 27, 2024 10:52 AM
Maybacks Global Entertainment Opens 23 More Stations in Important Major Cities • AHRO • Mar 27, 2024 9:00 AM
NxGen Brands Inc. Forecast to Deliver 140% Growth in Q1 2024 • NXGB • Mar 27, 2024 7:30 AM
Kona Gold Beverages, Inc. Strategic Advancements: Covert LLC Introduces Federally Legal D9 Gummies and Revamps Innovative eCommerce Platform, Propelling Toward $12 Million Annual Revenue Goal • KGKG • Mar 26, 2024 8:30 AM